Proteasome inhibition in multiple myeloma: Therapeutic implication

摘要: Normal cellular functioning requires processing of proteins regulating cell cycle, growth, and apoptosis. The ubiquitin-proteasome pathway (UBP) modulates intracellular protein degradation. Specifically, the 26S proteasome is a multienzyme protease that degrades misfolded or redundant proteins; conversely, blockade proteasomal degradation pathways results in accumulation unwanted death. Because cancer cells are more highly proliferative than normal cells, their rate translation also higher. This notion led to development inhibitors as therapeutics cancer. FDA recently approved first inhibitor bortezomib (Velcade), formerly known PS-341, for treatment newly diagnosed relapsed/refractory multiple myeloma (MM). Ongoing studies examining other novel inhibitors, addition bortezomib, MM cancers.